CPhI Japan 2023 was successfully concluded in Tokyo, Japan on April 19-21! This exhibition has been held annually since 2002, which is one of the series of pharmaceutical ingredients exhibitions held worldwide and has developed into the largest professional international pharmaceutical exhibition in Japan. CPCB was invited to participate in this forum and had a profound exchange and discussion with all the experts and their partners.
Chinese peptide company was invited to participate in 2023 CPhI Japan, and the exhibition site was crowded with people. The exhibition had more than 420 exhibitors from all over the world, and the audience reached a record high. Nearly 10,000 pharmaceutical industry professionals gathered together to participate in this event of the pharmaceutical industry. During the period, the exhibitors of Chinese peptide company introduced the latest research progress of the company in the leading fields of polypeptide and nucleic acid CRDMO service for the guests and colleagues in the industry, and the on-site exchanges were warm.
Founded in 2001, Chinese peptide company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.
The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.